製药和生物技术联合开发交易：2016-2025

《製药和生物技术共同开发》深入了解并分析了公司如何以及为何达成共同开发协议。

本报告提供了 2016 年至 2025 年联合开发案的详细资讯。提供了双方宣布的共同开发交易的付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判的交易条款的灵活性可以为谈判过程提供重要的见解，让您了解在谈判条款时会发生什么。许多小型企业都希望有详细的付款条款，但当涉及如何触发付款和权利转移时，细节决定成败。

本报告提供了自 2016 年以来宣布的合作交易的综合列表，这些交易记录在当前协议交易和联盟数据库中，包括可用的财务条款，并提供了公司及其合作伙伴向 SEC 提交的实际合作交易文件的在线副本链接。

本报告第一章涵盖联合开发交易和业务活动。

第 1 章对报告进行了介绍，第 2 章概述并分析了共同开发趋势，并讨论了该交易类型的好处。

第 3 章概述了共同开发专案的结构。

第 4 章回顾了 2016 年以来具有代表性的共同开发计画。交易按总金额列出。如果交易与美国证券交易委员会 (SEC) 发布了协议，则该连结可透过当前协议交易和联盟资料库在线存取该协议。

第 5 章提供了最活跃的 25 家联合开发交易製造商的综合清单。每个交易标题都透过我们的当前协议交易和联盟资料库连结到完整交易记录的线上版本，并在可用时连结到实际合约文件，从而可以轻鬆按需存取每个交易记录。

第 6 章全面详细地回顾了自 2016 年以来达成或宣布的联合开发交易，其中提供了合约文件，按公司 A-Z、治疗方式、技术和行业进行组织。合约文件详细介绍了双方就联合开发项目达成的实际商业条款。

交易目录包含自 2016 年以来宣布的所有合作交易的综合清单。每个清单都按公司 A-Z、治疗领域和技术类型组织为贸易目录。每个交易标题都透过超连结连结到交易记录的线上版本，包括实际的合约文件（如果有）。

该报告还包含大量图表和图形，展示了自 2016 年以来的共同开发交易趋势和活动。

总之，本报告提供了潜在交易者需要了解的有关联合开发联盟的所有资讯。

目录

摘要整理

第1章 简介

第2章 共同开发交易趋势

• 简介
• 联合开发交易的定义
• 2016 年以来共同开发交易的趋势
  • 2016 年至 2025 年联合开发交易量（按年份）
  • 2016 年至 2025 年联合开发交易（依开发阶段划分）
  • 2016 年至 2025 年联合开发交易（按行业划分）
  • 2016 年至 2025 年按治疗领域划分的共同开发交易
  • 2016 年至 2025 年联合开发交易（依技术类型划分）
  • 2016 年至 2025 年最活跃的共同开发交易（依公司划分）
• 签订联合开发协议的原因
• 联合开发协议的未来

第3章 共同开发交易结构概要

• 简介
• 共同开发交易结构

第4章 共同开发交易的主导

• 简介
• 主要的共同开发交易，各金额

第5章 -最活跃的共同开发交易厂商主要25公司

• 简介
• 最活跃的共同开发交易厂商主要25公司

包含第6章 -契约名录的共同开发交易

• 简介
• 按从2016年到2025年的契约共同开发交易
• 交易名录
• 交易名录- 各企业共同开发交易(AZ)
• 交易名录- 共同开发交易，各治疗领域
• 交易名录- 共同开发交易，各技术类型
• 关于调查公司
• 目前联盟
• 目前契约
• Current Partnering的最近的报告标题

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.

Fully revised and updated, the report provides details of co-development deals from 2016 to 2025.

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals.

Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.

The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.

Key benefits

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse co-development deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Co-development Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading biopharma companies worldwide.

Co-development Deals in Pharmaceuticals and Biotechnology includes:

• Trends in co-development dealmaking in the biopharma industry
• Overview of co-development deal structure
• Directory of co-development deal records covering pharmaceutical and biotechnology
• The leading co-development deals by value
• Most active co-development dealmakers
• The leading co-development partnering resources

In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Co-development Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for co-development deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking

• 2.1. Introduction
• 2.2. Definition of co-development deal
• 2.3. Trends in co-development deals since 2016
  • 2.3.1. Co-development dealmaking by year, 2016-2025
  • 2.3.2. Co-development dealmaking by phase of development, 2016-2025
  • 2.3.3. Co-development dealmaking by industry sector, 2016-2025
  • 2.3.4. Co-development dealmaking by therapy area, 2016-2025
  • 2.3.5. Co-development dealmaking by technology type, 2016-2025
  • 2.3.6. Co-development dealmaking by most active company, 2016-2025
• 2.4. Reasons for entering into co-development partnering deals
• 2.5. The future of co-development deals

Chapter 3 - Overview of co-development deal structure

• 3.1. Introduction
• 3.2. Co-development agreement structure

Chapter 4 - Leading co-development deals

• 4.1. Introduction
• 4.2. Top co-development deals by value

Chapter 5 - Top 25 most active co-development dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active co-development dealmakers

Chapter 6 - Co-development deals including contracts directory

• 6.1. Introduction
• 6.2. Co-development deals with contracts 2016-2025
• Deal directory
• Deal directory - co-development dealmaking by companies A-Z
• Deal directory - co-development dealmaking by therapy area
• Deal directory - co-development dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of co-development deal
• Figure 2: Trends in co-development deal announcements, 2016-2025
• Figure 3: Co-development deals signed at each phase of development, 2016-2025
• Figure 4: Co-development deals by industry sector, 2016-2025
• Figure 5: Co-development deals by therapy area, 2016-2025
• Figure 6: Co-development deals by technology type, 2016-2025
• Figure 7: Top 25 most active co-development dealmakers, 2016-2025
• Figure 8: Top co-development deals by value, 2016-2025
• Figure 9: Most active co-development dealmakers, 2016-2025